HNF-3 beta/FoxA2 Antibody (OTI3C10)

Flow Cytometry: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088]

Flow Cytometry: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] - HEK293T cells transfected with either pCMV6-ENTRY FOXA2.(Red) or empty vector control plasmid (Blue) were immunostained with anti-FOXA2 mouse monoclonal, and then analyzed by flow cytometry.

Western Blot: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088]

Western Blot: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY FOXA2 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-FOXA2.

Immunocytochemistry/ Immunofluorescence: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088]

Immunocytochemistry/Immunofluorescence: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] - Staining of HeLa cells transiently transfected by pCMV6-ENTRY FOXA2.

Immunohistochemistry-Paraffin: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088]

Immunohistochemistry-Paraffin: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] - Staining of paraffin-embedded Carcinoma of liver using anti-FOXA2 mouse monoclonal antibody.

Western Blot: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] -

FOXA2 knockdown induces ferroptosis in chemoresistant CRC cell lines. A) RT‐qPCR analysis for Nrf2, NQO1, SOD1, GPX4 and SLC7A11 gene expression levels in drug‐sensitive or ‐resistant HCT‐116 and SW480 cells (n = 3). B) Western blot assay for GPX4, Nrf2, and NQO1 protein expression levels in HCT‐116 and SW480 cells with or without chemoresistance (n = 4). C) Western blot assay for FOXA2, GPX4, Nrf2, and NQO1 protein expression levels in chemoresistant HCT‐116 and SW480 cells with or without FOXA2 knockdown (n = 4). (D) GPX4 expression by IF staining in drug‐resistant CRC cells after transfection with sh‐FOXA2 (n = 4). Scale bar = 20 um. E) ROS and (F) lipid ROS production by DCF‐DA (Scale bar = 50 um) and C11‐BODIPY581/591 (Scale bar = 20 um) staining, respectively, in chemoresistant HCT‐116 and SW480 cells with FOXA2 knockdown (n = 4). G) MDA levels, H) GSH contents, and I) iron currents in drug‐resistant HCT‐116 and SW480 cells after FOXA2 knockdown (n = 4). Data are marked as the means +/- SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37875418), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] -

FOXA2 expression is up‐regulated in CRC patients. A,B) FOXA2 expression profile in CRC tissues from TCGA cohort. C) Representative IHC images for FOXA2 in CRC tissues and normal tissues (https://www.proteinatlas.org/). D) Kaplan‐Meier analysis for relapse‐free‐survival (RFS) of CRC patients with high (n = 709) or low (n = 633) FOXA2 expression based on the median expression of FOXA2 from the Kaplan‐Meier Plotter (https://kmplot.com/analysis/index.php?p = service). E) Images of IHC staining for FOXA2 in CRC tissues and the paired adjacent normal tissues from our cohort. Scale bar = 120 um. F) IHC scores of FOXA2 expression levels in paired normal and CRC samples were quantified. G) RT‐qPCR analysis for FOXA2 gene expression in human CRC tissues and the matched adjacent normal tissues (ANT) from our cohort (n = 60). H) FOXA2 protein expression in eighteen paired CRC tissues was examined using western blot. I) RT‐qPCR (n = 5) and J) western blot (n = 4) assays for FOXA2 gene and protein expression levels in six CRC cell lines and non‐tumor cell line NCM460. Data are marked as the means +/- SD. *p < 0.05, **p < 0.01, ****p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37875418), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] -

Conditional knockout of FOXA2 in IECs ameliorates colitis‐associated tumorigenesis in vivo. A) Scheme protocols of recombination in Villin‐Cre; FOXA2f/f mice. B,C) RT‐qPCR and western blot assays for FOXA2 gene and protein expression levels in colon crypts from the mice treated with or without AOM/DSS (n = 6). D) H&E and IHC staining of FOXA2 in colon from FOXA2f/f and FOXA2cKO mice (n = 8). Scale bar = 120 um. E) Inflammation scores were quantified. (F) FOXA2 expression by IHC staining was calculated. G) Body weights of mice were recorded (n = 10–15 in each group). H) Overall survival rates for each group of mice (n = 10–15 in each group). I) Images for colons from all groups of mice. J) Colon length was measured (n = 15). (K) Tumor number on colon was examined (n = 15). L) IHC staining for KI‐67 in colon tissues was performed (n = 5). Scale bar = 50 um. Data are marked as the means +/- SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significant difference. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37875418), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Knockdown Validated: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] -

Positive correlation between FOXA2 and Nrf2/GPX4 signaling in CRC cell lines. A) Positive correlation between FOXA2 expression and GPX4, NFE2L2 (Nrf2), NQO1, G6PD, and SLC7A11 in CRC patients from TCGA database. B) RT‐qPCR analysis for genes including Nrf2, GCLC, NQO1, SOD1, GPX4, SLC7A11 and G6PD in HCT‐116 and SW480 cells with FOXA2 knockdown or over‐expression (n = 3). C,D) IF staining for GPX4 expression in CRC cell lines transfected with sh‐FOXA2 or oe‐FOXA2 (n = 4). Scale bar = 20 um. E) Western blot analysis for GPX4, Nrf2, and NQO1 protein expression levels in FOXA2‐diminished or ‐over‐expressed HCT‐116 and SW480 cells (n = 3). Data are marked as the means +/- SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37875418), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] -

Conditional knockout of FOXA2 in IECs ameliorates colitis‐associated tumorigenesis in vivo. A) Scheme protocols of recombination in Villin‐Cre; FOXA2f/f mice. B,C) RT‐qPCR and western blot assays for FOXA2 gene and protein expression levels in colon crypts from the mice treated with or without AOM/DSS (n = 6). D) H&E and IHC staining of FOXA2 in colon from FOXA2f/f and FOXA2cKO mice (n = 8). Scale bar = 120 um. E) Inflammation scores were quantified. (F) FOXA2 expression by IHC staining was calculated. G) Body weights of mice were recorded (n = 10–15 in each group). H) Overall survival rates for each group of mice (n = 10–15 in each group). I) Images for colons from all groups of mice. J) Colon length was measured (n = 15). (K) Tumor number on colon was examined (n = 15). L) IHC staining for KI‐67 in colon tissues was performed (n = 5). Scale bar = 50 um. Data are marked as the means +/- SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significant difference. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37875418), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HNF-3 beta/FoxA2 Antibody (OTI3C10) [NBP2-02088] -

Conditional knockout of FOXA2 in IECs ameliorates colitis‐associated tumorigenesis in vivo. A) Scheme protocols of recombination in Villin‐Cre; FOXA2f/f mice. B,C) RT‐qPCR and western blot assays for FOXA2 gene and protein expression levels in colon crypts from the mice treated with or without AOM/DSS (n = 6). D) H&E and IHC staining of FOXA2 in colon from FOXA2f/f and FOXA2cKO mice (n = 8). Scale bar = 120 um. E) Inflammation scores were quantified. (F) FOXA2 expression by IHC staining was calculated. G) Body weights of mice were recorded (n = 10–15 in each group). H) Overall survival rates for each group of mice (n = 10–15 in each group). I) Images for colons from all groups of mice. J) Colon length was measured (n = 15). (K) Tumor number on colon was examined (n = 15). L) IHC staining for KI‐67 in colon tissues was performed (n = 5). Scale bar = 50 um. Data are marked as the means +/- SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significant difference. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37875418), licensed under a CC-BY license. Not internally tested by Novus Biologicals.